This study is testing a new drug called RLY-2608, which targets a specific gene mutation called PIK3CA. This mutation can cause overgrowth and other problems in the body. The study has three parts: the first part finds the right dose; the second part examines different groups of people to see how they respond; and the third part compares the drug to a placebo (a pill with no medicine).
Key Points:
- Participants should be diagnosed with a condition related to the PIK3CA mutation.
- Some medical history or conditions may exclude you from participating.
- Participation may involve providing tissue samples or blood for testing.
To join, you must have a PIK3CA mutation or similar issues, and be willing to provide tissue samples if needed. You can’t join if you have had certain treatments recently or have heart issues.
How understandable was the trial content above?
Hard to understand
Easy to understand